Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Goldman Sachs analyst Chris Shibutani adjusted the price target for Merck (NSE:PROR) & Co. Inc. (NYSE:MRK) to $129.00, down from the previous $135.00, while reiterating a Buy rating on the ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Leverage these to understand future stock performance and identify high ... Alphabet, Advanced Micro, Merck, Amgen, and PepsiCo; on Wednesday, Novo Nordisk, Qualcomm, Uber, and Disney; on Thursday ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Lions Gate Entertainment Corp. Cl A 3.38% $1.77B ...